Andreas Bernkop-Schnürch

Edit links
Source: Wikipedia, the free encyclopedia.

Andreas Bernkop-Schnürch (born in Klagenfurt, December 6, 1965) is an Austrian scientist and entrepreneur, who is Head of the Department of Pharmaceutical Technology in the Institute of Pharmacy at the University of Innsbruck.

His research centers on the areas of drug delivery, dosage forms, controlled release, bionanotechnology, polymer engineering and tissue engineering. He is the inventor of several technologies, such as thiolated polymers, [1][2] for which he coined the name thiomers in 2000,[3] and phosphatase triggered charge-converting nanoparticles for mucosal drug delivery.[4]

Bernkop-Schnürch has been on the scientific advisory board of the Nicotine Science Center

Horizon 2020
.

Andreas Bernkop-Schnürch is the founder of Thiomatrix Forschungs- und Beratungs GmbH, Mucobiomer Biotechnologische Forschungs- und Entwicklungs GmbH (now part of the Croma-Pharma GmbH) and Green River Polymers Forschungs und Entwicklungs GmbH. He has been listed as a Highly Cited Researcher of the Institute for Scientific Information[7] since 2022.



Biography

Andreas Bernkop-Schnürch comes from an Austrian apothecary family. He was educated in pharmacy and in microbiology and genetics at the

pharmaceutical technology. Since 2003, he has held the chair in pharmaceutical technology at the University of Innsbruck, heading the Department of Pharmaceutical Technology.[8] From 2006 to 2013, he served as dean of the Faculty of Chemistry and Pharmacy.[9] In 2022, he was a visiting professor at the University of Bari Aldo Moro. He has been a member of the senate of the University of Innsbruck
since 2021.

Research

Andreas Bernkop-Schnürch is known for his research on

cyclodextrins, which he introduced in 2015,[17]
providing in particular a prolonged residence time on mucosal membranes,[18][19][20] exhibiting permeation enhancing[21] as well as efflux pump inhibiting properties,[22] and improving cellular uptake.[23] Furthermore, Andreas Bernkop-Schnürch pioneered charge-converting nanoparticles for mucosal drug delivery utilizing the membrane bound enzyme alkaline phosphatase to trigger a shift in zeta potential from negative to positive directly at the epithelium.[4] Cationic nanoparticles are more efficiently taken up by epithelial cells than anionic ones. However, they do not reach epithelial cells, as they are immobilized via ionic interactions in mucus, displaying an anionic charge because of sialic acid substructures. Charge-converting nanoparticles address this so-called ‘polycation dilemma’ by converting their surface charge to positive at the cellular membrane.[24] Moreover, Andreas Bernkop-Schnürch contributed basic knowledge to the field of self-emulsifying drug delivery systems (SEDDS) for mucosal delivery of macromolecular drugs.[25]

Editing

Bernkop-Schnürch is on the editorial board of numerous pharmaceutical journals, including the International Journal of Pharmaceutics, the Journal of Drug Delivery Science and Technology, Scientia Pharmaceutica, Drug Development and Industrial Pharmacy, and the European Journal of Pharmaceutics and Biopharmaceutis.

Awards

Andreas Bernkop-Schnürch has been awarded more than 20 national and international awards. These include:

  • Research-Award of the City of Vienna 1999[26]
  • Eurand-Award 2000[27]
  • Best of Biotech Award 2001[28]
  • MBPW Award 2002[29]
  • Best of Biotech Award 2003[30]
  • Adventure X Award 2004[31]
  • Most Cited Paper Awards 2004 [32][33]
  • Phoenix Science Award for Pharmacy 2005[34]
  • Eurand Award 2007[35]
  • Austrian Nano Award 2008[36]
  • Ernst Brandl Award 2015[37]
  • Most Cited Paper Award 2017 [38]
  • Gattefossé North America Award for Excellence in Research & Development with Lipid Excipients 2017[39]
  • Phoenix Science Award for Pharmacy 2022[40]
  • Science Award of Tyrol (de:Tiroler Landespreis für Wissenschaft) 2023[41]

Selected works

Andreas Bernkop-Schnürch is author of over 500 research articles and reviews, as well as editor and (co-)author of several books.


References

  1. ^ a b AT 269105T, Andreas Bernkop-Schnürch, "Verfahren zur Verbesserung der Mucoadhäsion von Polymeren sowie deren Herstellung und Verwendung", published 1998-11-04  and following patents such as EP1126881B1, US7354600B1, CN1325312A, JP4744693B2.
  2. ^
    PMID 16176846
    .
  3. PMID 10708877
    .
  4. ^
    S2CID 245865286
    .
  5. ^ "Nicotine Science Center". Archived from the original on 29 July 2016. Retrieved 12 June 2016.
  6. ^ "Scientific Committee of IMI". Archived from the original on 11 July 2017. Retrieved 16 November 2016.
  7. ^ Cite web |url=https://clarivate.com/highly-cited-researchers/
  8. ^ Gehwolf, Severin; Gstrein, Elisabeth. "Institut für Pharmazie / Institute of Pharmacy". University of Innsbruck. Retrieved 12 April 2023.
  9. ^ "Kopf der Woche: Dekan Andreas Bernkop-Schnürch". 8 May 2006.
  10. ^ "Search of: chitosan-n-acetylcysteine - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 12 April 2023.
  11. ^ "Search of: thiomer - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 12 April 2023.
  12. ^ "Cataract & Refractive Surgery Today Europe - Trials Underway for Thiomer-Based Dry Eye Treatment". Archived from the original on 29 July 2016. Retrieved 15 July 2016.
  13. PMID 12695025
    .
  14. PMID 30966278
    .
  15. PMID 32567846
    .
  16. PMID 34773391
    .
  17. PMID 26256340
    .
  18. PMID 35269753
    .
  19. S2CID 253216810
    .
  20. S2CID 224881946
    .
  21. PMID 37985088
    .
  22. PMID 38171673
    .
  23. PMID 37321712
    .
  24. PMID 35932682
    .
  25. S2CID 51599514
    .
  26. ^ "Förderungspreise der Stadt Wien, Preisträger Naturwissenschaft seit 1991". Archived from the original on 29 July 2016. Retrieved 13 June 2016.
  27. ^ "PR Newswire France | Dernieres actualites". www.prnewswire.com (Press release). Retrieved 12 April 2023.
  28. ^ "derStandard.at". www.derstandard.at. Retrieved 12 April 2023.
  29. ^ "Events Founders Forum Kontakte, Kontakte, Kontakte - PDF Free Download". docplayer.org. Retrieved 12 April 2023.
  30. ^ "Beteiligung an "BOB - Best of Biotech" übertrifft alle Erwartungen. Bereits 97 Einreichungen in Phase 1 des Businessplan-Wettbewerbs für Life Sciences". OTS.at. Retrieved 12 April 2023.
  31. ^ "Startup.Euregio - ein dynamisches und nachhaltiges Ökosystem – Startup.Euregio". www.startupeuregio.eu. Retrieved 12 April 2023.
  32. ^ "Most Cited Paper Award 2004 JCR" (PDF). Retrieved 12 April 2023.
  33. ^ "Most Cited Paper Award 2004 EJPS" (PDF). Retrieved 12 April 2023.
  34. ^ "PHOENIX Pharmazie Wissenschaftspreis 2005 an Rollinger und Bernkop-Schnürch". Universität Innsbruck. 14 November 2005. Retrieved 12 April 2023.
  35. ^ "Pharma commercial intelligence, news & analysis | Evaluate". www.evaluate.com. Retrieved 12 April 2023.
  36. ^ Kinzl, Martina (4 December 2008). "Auszeichnung für Spitzenleistung in Nanowissenschaften". Universität Innsbruck. Retrieved 12 April 2023.
  37. ^ Bartos, Melanie (12 June 2015). "Pharmazeut mit Prof. Ernst-Brandl-Preis ausgezeichnet". Universität Innsbruck. Retrieved 12 April 2023.
  38. ^ "Most Cited Paper Award 2017 EJPB JCR" (PDF). Retrieved 12 April 2023.
  39. ^ "Gattefossé North America Announces Recipient of 2017 Award for Excellence | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology". Retrieved 12 April 2023.
  40. ^ "Wissenschaftspreis". www.phoenixgroup.eu. Retrieved 12 April 2023.
  41. ^ "Andreas Bernkop-Schnürch erhält Tiroler Landespreis für Wissenschaft". science.apa.at. 16 August 2023. Retrieved 16 August 2023.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Andreas_Bernkop-Schnürch&oldid=1220541224"